Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/7/2017
SIETES contiene 91904 citas

 
 
 1 a 20 de 2112 siguiente >>
Presentar resultados
Seleccionar todas
2. Cita con resumen
Anónimo. FDA approves guselkumab for treatment of plaque psoriasis. DIA Daily 2017:2. [Ref.ID 101909]
3.Enlace a cita original Cita con resumen
Bouvy JC, Blake K, Slattery J, De Bruin ML, Arlett P, Kurz X. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005–2013. Pharmacoepidemiol Drug Saf 2017;26:agosto. [Ref.ID 101903]
4. Cita con resumen
Xu J, Emenanjo O, Ortwerth M, Lurie P. Association of appearance of conflicts of interest with voting behavior at FDA advisory committee meetings—A cross-sectional study. JAMA Intern Med 2017;177:1038-40. [Ref.ID 101664]
5. Cita con resumen
6. Cita con resumen
Anónimo. FDA announces list of off-patent drugs with no competition. DIA Daily 2017:1. [Ref.ID 101658]
7. Cita con resumen
Huang Z, Ma J. Chronic purulent nasal discharge. BMJ 2017;357:j2061. [Ref.ID 101636]
8. Cita con resumen
9. Cita con resumen
Al-Khateeb Z, Hadker N, Scaife JG, Miyasato G, Sanchez H. What we value: the proposition behind the price. Trinity Partners 2017:26 de mayo. [Ref.ID 101602]
10. Cita con resumen
Anónimo. EMA’s CHMP recommends approval of biosimilar insulin lispro. DIA Daily 2017:2. [Ref.ID 101598]
11. Cita con resumen
Downing NS, Shah ND, Aminawung JA, Pease AM, Zeitoun JD, Krumholz HM, Ross JS. Postmarket safety events among novel therapeutics approved by the US Food and Drug Administration between 2001 and 2010. JAMA 2017;317:1854-63. [Ref.ID 101567]
14. Cita con resumen
Schick A, Miller KL, Lanthier M, Pan GD, Nardinelli C. Evaluation of pre-marketing factors to predict post-marketing boxed warnings and safety withdrawals. Drug Saf 2017:24 de marzo. [Ref.ID 101505]
15. Cita con resumen
Anónimo. Crisaborole (Eucrisa) for atopic dermatitis. The Medical Letter on Drug and Therapeutics Bulletin 2017;59:34-5. [Ref.ID 101487]
16. Cita con resumen
Anónimo. FDA pushes back on Trump’s claims of slow drug reviews. DIA Daily 2017:8. [Ref.ID 101452]
18. Cita con resumen
Anónimo. Pembrolizumab (Keytruda) for first-line treatment of metastatic NSCLC. Med Lett Drugs Ther 2017;59:22-3. [Ref.ID 101421]
19. Cita con resumen
Anónimo. Lixisenatide for type 2 diabetes. Med Lett Drugs Ther 2017;59:19-21. [Ref.ID 101420]
20.Tiene citas relacionadas Cita con resumen
Wong J, Motulski A, Abrahamowicz M, McGill J, Eguale T, Buckeridge DL, Tamblyn R. Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system. BMJ 2017;356:j603. [Ref.ID 101417]
Seleccionar todas
 
 1 a 20 de 2112 siguiente >>